Table 2 Length of follow-up of enrolled patients
| Â | Pirfenidone treatment | No-antifibrotic treatment |
|---|---|---|
Length of follow-up (months, mean ± SD) | 22.8 ± 16.5 | 32.1 ± 37.3 |
Number of patients at the treatment initiation | 383 (100.0%) | 218 (100.0%) |
at posttreatment follow-up (in months): | ||
 6 (±1) mo | 331 (86.4%) | 174 (79.8%) |
 12 (±1) mo | 270 (70.5%) | 144 (66.1%) |
 18 (±2) mo | 204 (53.3%) | 117 (53.7%) |
 24 (±2) mo | 138 (36.0%) | 98 (45.0%) |
 60 (±3) mo | 17 (4.4%) | 32 (14.7%) |